Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000929638-25-001925·Prelude Therapeutics Inc
Schedule 13G ownership disclosure
Prelude Therapeutics, Inc.
Common Stock, par value $0.0001 per share · CUSIP: 74065P101
Event date: 2025-03-31
- Filing-level shares
- 6,397,839
- Percent of class
- 13.8%
- Vaddi Krishna
Shares: 6,397,839 · Class: 13.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-25-001925
- Form type
- SCHEDULE 13G/A
- Filer
- Prelude Therapeutics Inc
- CIK
- CIK 1678660
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership